| Autor: |
Bezrookove V; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., Patino JM; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., Nosrati M; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., Desprez PY; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., McAllister S; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., Soroceanu L; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., Baron A; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., Osorio R; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., Kashani-Sabet M; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA., Dar AA; California Pacific Medical Center Research Institute, 475 Brannan St., Suite 130, San Francisco, CA 94107, USA. |
| Abstrakt: |
Cholangiocarcinoma (CCA) is the second most common hepatobiliary cancer, an aggressive malignancy with limited therapeutic options. PARP (poly (ADP-ribose) polymerase) 1 and 2 are important for deoxyribonucleotide acid (DNA) repair and maintenance of genomic stability. PARP inhibitors (PARPi) such as niraparib have been approved for different malignancies with genomic alteration in germline BRCA and DNA damage response (DDR) pathway genes. Genomic alterations were analyzed in DDR genes in CCA samples employing The Cancer Genome Atlas (TCGA) database. Mutations were observed in various DDR genes, and 35.8% cases had alterations in at least one of three genes ( ARID1A , BAP1 and ATM ), suggesting their susceptibility to PARPi. Niraparib treatment suppressed cancer cell viability and survival, and also caused G2/M cell cycle arrest in patient-derived xenograft cells lines (PDXC) and established CCA cells harboring DDR gene mutations. PARPi treatment also induced apoptosis and caspase3/7 activity in PDXC and CCA cell lines, and substantially reduced expression of BCL2, BCL-XL and MCL1 proteins. Niraparib caused a significant increase in oxidative stress, and induced activation of DNA damage markers, phosphorylation of CHK2 and replication fork stalling. Importantly, niraparib, in combination with gemcitabine, produced sustained and robust inhibition of tumor growth in vivo in a patient-derived xenograft (PDX) model more effectively than either treatment alone. Furthermore, tissue samples from mice treated with niraparib and gemcitabine display significantly lower expression levels of pHH3 and Ki-67, which are a mitotic and proliferative marker, respectively. Taken together, our results indicate niraparib as a novel therapeutic agent alone or in combination with gemcitabine for CCA. |
